Detail

Study ID: BMS CA022-001

Title:

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

Description:
Title: CA022-001 Description: This is a phase 1/2a, open-label study of BMS-986218 given alone or in combination with Nivolumab in patients with advanced solid tumors. This study has two parts, dose escalation (Part 1A/1B) and dose expansion (Part 2A/2B).
Location:
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Disease:
Solid Tumors
Stage:
Phase I/II
Status:
Active - Open to Accrual